Neurogenesis, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEUN research report →
Companywww.neurogenesis.com
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol.
- CEO
- Tal Gilat
- IPO
- 1998
- Employees
- 24
- HQ
- League City, TX, US
Price Chart
Valuation
- Market Cap
- $8.23K
- P/E
- 0.53
- P/S
- 0.02
- P/B
- -0.08
- EV/EBITDA
- 3.95
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 73.01%
- Op Margin
- 8.23%
- Net Margin
- 3.91%
- ROE
- -12.02%
- ROIC
- 78.67%
Growth & Income
- Revenue
- $399.16K · -15.31%
- Net Income
- $15.61K · 147.82%
- EPS
- $0.00 · 140.00%
- Op Income
- $32.86K
- FCF YoY
- -1534.82%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -17.40
- Avg Volume
- 2.00K
Get TickerSpark's AI analysis on NEUN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NEUN Coverage
We haven't published any research on NEUN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NEUN Report →